Global conjunctivitis market to hit $7.2b by 2033

It is driven by rising cases of bacterial, viral, and allergic conjunctivitis

The global conjunctivitis market, valued at $4.8b in 2023, is expected to reach $7.2b by 2033, according to Allied Market Research.

The growth is driven by rising cases of bacterial, viral, and allergic conjunctivitis, demand for fast-acting and preservative-free treatments, and advances in diagnostics and drug delivery.

Increased awareness of eye hygiene and wider access to care in emerging markets also support expansion, though misdiagnosis and limited specialist access in some regions could slow growth.

In 2023, the treatment segment held the largest share of the market, driven by high demand for antibiotics, antiviral drugs, anti-allergic eye drops, and artificial tears. Hospitals, specialty clinics, and retail pharmacies routinely use these therapies for managing bacterial, viral, and allergic conjunctivitis. Rising prevalence of eye infections and seasonal allergy outbreaks further bolster this segment.

Allergic conjunctivitis accounted for the largest share in 2023, influenced by seasonal and perennial allergies, the report noted.

Seasonal allergic conjunctivitis is prevalent in areas with high pollen exposure, whilst perennial forms result from dust, pet dander, and environmental irritants. Increasing allergies, urbanization, and environmental pollution are driving demand for anti-allergic treatments and supportive eye care products.

Hospitals and clinics represented the largest end-user segment in 2023, serving a high patient volume for diagnostics and treatment, ranging from routine eye exams to severe infections.

The adoption of advanced diagnostic tools, laboratory testing, and tele-ophthalmology services enhances treatment efficiency. Specialty eye clinics also contribute significantly through focused care and rapid access to advanced therapeutics.